.beta.1,3-n-acetyl-d-galactosaminyltransferase protein and nucleic acid encoding the same, as well as canceration assay using the same
CA 2517469 C · Owner: Fujirebio Inc. · Inventors: Hiruma, Toru; Narimatsu, Hisashi; Ishizuka, Yasuko
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
An N-acetyl-D-galactosamine transferase protein characterized by transferring N-acetyl-D-galactosamine to N-acetyl-D-glucosamine via a .beta.1,3-bond. It preferably has an amino sequence represented by SEQ ID NO:2 or 4. A method of examining canceration by using a nucleic acid for assaying which is hybridizable under stringent conditions with a base sequence represented by SEQ ID NO:1 or 3 or a base sequence being complementary to at least one of these base sequences.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 23, 2004 and granted March 17, 2015. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 23, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 23, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.